The estimated Net Worth of Eyal C. Attar is at least $1.48 Milion dollars as of 28 February 2022. Eyal Attar owns over 36,000 units of Aprea Therapeutics stock worth over $151,340 and over the last 5 years he sold APRE stock worth over $137,010. In addition, he makes $1,189,280 as Senior Vice President a Chief Medical Officer at Aprea Therapeutics.
Eyal has made over 3 trades of the Aprea Therapeutics stock since 2019, according to the Form 4 filled with the SEC. Most recently he sold 36,000 units of APRE stock worth $62,280 on 28 February 2022.
The largest trade he's ever made was selling 36,000 units of Aprea Therapeutics stock on 28 February 2022 worth over $62,280. On average, Eyal trades about 6,546 units every 109 days since 2019. As of 28 February 2022 he still owns at least 47,000 units of Aprea Therapeutics stock.
You can see the complete history of Eyal Attar stock trades at the bottom of the page.
Dr. Eyal C. Attar M.D. serves as Senior Vice President, Chief Medical Officer of the Company. Dr. Attar joined Aprea from Agios Pharmaceuticals, a pharmaceutical company, where he was Senior Medical Director from 2016 to 2019, IDH Hematology Medical Lead from 2016 to 2019 and Medical Director from 2014 to 2016. While serving at Agios, Dr. Attar played a leadership role in the clinical development and approval of IDHIFA and TIBSOVO for patients with relapsed/refractory AML. Prior to Agios, he served on the clinical staff at the Massachusetts General Hospital Cancer Center, where Dr. Attar was a member of the Center for Leukemia and Assistant Professor of Medicine at Harvard Medical School. He completed his residency in Internal Medicine at Brigham and Women’s Hospital and held fellowships in hematology and oncology in the Dana-Farber Partners Cancer Care Hematology/Oncology Fellowship Program. Dr. Attar received his medical degree from the University of North Carolina School of Medicine.
As the Senior Vice President a Chief Medical Officer of Aprea Therapeutics, the total compensation of Eyal Attar at Aprea Therapeutics is $1,189,280. There are 2 executives at Aprea Therapeutics getting paid more, with Christian Schade having the highest compensation of $3,677,570.
Eyal Attar is 49, he's been the Senior Vice President a Chief Medical Officer of Aprea Therapeutics since 2019. There are 15 older and 2 younger executives at Aprea Therapeutics. The oldest executive at Aprea Therapeutics, Inc. is Guido Magni, 67, who is the Independent Director.
Over the last 5 years, insiders at Aprea Therapeutics have traded over $63,126,246 worth of Aprea Therapeutics stock and bought 2,073,560 units worth $29,606,912 . The most active insiders traders include Group, Llc Green Jeremy Red..., Vantage I, L.P.Versant Vant... a John B Iii Henneman. On average, Aprea Therapeutics executives and independent directors trade stock every 43 days with the average trade being worth of $420,918. The most recent stock trade was executed by John P. Hamill on 13 March 2024, trading 1,010 units of APRE stock currently worth $7,363.
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. Its lead product candidate is ATRN-119, an oral ATR inhibitor that is in phase 1/2a clinical trial to treat patients with advanced solid tumors. The company's products pipeline also includes ATRN-Backup, an ATR inhibitor; ATRN-W1051 to treat anti-tumor activity; and ATRN-DDRi. Aprea Therapeutics, Inc. is based in Boston, Massachusetts.
Aprea Therapeutics executives and other stock owners filed with the SEC include: